 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
|
||||||||||||||||
Grant: Investigation of inhibitory effects of the multipotent drug Artesunate against HHV-6 PI: Manfred Marschall, PhD, Universität Erlangen-Nürnberg, Germany Artesunate (“ART”), a drug FDA approved for malaria, has also shown efficacy against CMV in preliminary studies. Because the replication efficiency of herpesviruses use the same cellular activation pathways, Dr. Manfred Marschall of the Institute of Clinical and Molecular Virology at the University of Eriangen-Nuremberg in Germany, has postulated that HHV-6 replication could be inhibited by mechanisms similar to CMV with the use of ART treatment. Preliminary studies of ART both in vivo and in vitro demonstrated significant decreased replication in the herpes viruses tested, including CMV, HSV-1 and Epstein-Barr Virus. The in vivo study in rats showed that ART inhibits CMV dissemination to or infection of the salivary glands as well as significantly reduced viral DNA load and virus titers. Additionally, ART shows no signs of cytotoxicity and is orally bioavailable. Dr. Marschall plans to investigate the specific effect of ART on the replication of HHV-6 with the ultimate goal of developing a therapeutic compound effective against HHV-6. Additionally, Dr. Marschall aims to understand HHV-6 resistance formation as well as the specific ART mode of action and it’s parallels with CMV.
|
 |
||
 |
 |
 |
 |
||